Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and Cancer Treatment and Pharmacology.
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR
A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
A Phase <scp>IIb</scp>, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for <i>BRCA</i> Carriers.
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with <scp>HER2</scp>‐positive advanced breast cancer (<scp>PRETTY</scp>): A nationwide, prospective, observational study